Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07133308 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
A Phase 3 study of Alopecia Areata, sponsored by Sun Pharmaceutical Industries.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 355
- Enrollment target
- 20
- Study locations
NCT07133308: Recruiting Phase 3 study of Alopecia Areata, sponsored by Sun Pharmaceutical Industries.
NCT07133308 is a Phase 3 study of Alopecia Areata that is actively recruiting participants, run by Sun Pharmaceutical Industries. The registered enrollment target is 355 participants, below the 1,942-participant average among 26 other Alopecia Areata trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07133308, a Phase 3 study of Alopecia Areata, is actively recruiting participants, sponsored by Sun Pharmaceutical Industries.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 355 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
Primary Outcome
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Deuruxolitinib
Study Locations (20)
Florida
- D&H Doral Research Center - Doral
- Skin Care Research, Llc - Hollywood - Hollywood
- Ilumina Medical Research Llc - Kissimmee
- All X Ray Diagnostic Services Corp - Miami
- Millennium Medical Research Llc - Miami
- Florida International Medical Research - Miami
- Florida Pharmaceutical Research And Associates, Inc. - Miami
- L&C Professional Medical Research Institute - Miami
- Pediatric Skin Research Llc - Miami
- Valencia Medical & Research Center - Miami
California
- Kern Research Inc. - Bakersfield
- Center For Dermatology Clinical Research Inc. - Fremont
- Dermatology Research Associates - Los Angeles
- Palmtree Clinical Research - Palm Springs
- Paradigm Clinical Research - San Diego - San Diego
Colorado
- Colorado Medical Research Center - Denver
- Paradigm Clinical Research - Wheat Ridge - Wheat Ridge
Alabama
- Total Skin And Beauty Dermatology Center - Birmingham
Arizona
- Avacare - Cct Research - Center For Dermatology And Plastic Surgery - Scottsdale
Arkansas
- Dermatology Trial Associates - Bryant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2025-08-05 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
What NCT07133308 shows while recruiting
NCT07133308 is an interventional study that assigns participants to a tested intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap, below the 1,942-participant average among 26 other Alopecia Areata trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07133308 names 20 study sites across 6 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT07133308 about?
NCT07133308 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata". This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
What is the current status of trial NCT07133308?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 355 participants. The study started on 2025-08-05. Estimated completion is 2028-05.
What conditions does trial NCT07133308 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT07133308?
The interventions under investigation include: Placebo (DRUG), Deuruxolitinib (DRUG).
Who is sponsoring clinical trial NCT07133308?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07133308 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07133308's enrollment target sits among peer trials
355 11th of 26 higher than 16 of 26 other Alopecia Areata trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
RECRUITING · Phase 3
-
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
RECRUITING · Phase 3
-
Long-Term PF-06651600 for the Treatment of Alopecia Areata
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07193511 · 355 participants · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
- NCT06958328 · 356 participants · Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI